文献速递银屑病与炎症性皮肤病

阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病:单盲随机对照试验三年随访数据

Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-04-17

该多中心随机对照试验纳入61例中重度斑块状银屑病患者,比较阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗,随访至145周。结果显示联合组与单药组总体药物生存率无显著差异,联合组因不良事件停药常见,作者认为可在个体患者中考虑联合治疗。

要点

  • 第109周药物生存率联合组54.8% vs 单药组41.4%(p=0.326),第145周联合组51.6% vs 单药组41.4%(p=0.464),均无显著差异。
  • 第145周时,联合组13例中7例仍使用甲氨蝶呤;单药组完成研究的12例中4例产生抗药抗体,联合组13例中3例产生抗药抗体。
  • 联合组因不良事件停药常见;作者认为为保障医疗可及性,可在个体患者中考虑阿达木单抗联合甲氨蝶呤治疗。

核心结论

  • 在这项小型研究中,与阿达木单抗单药相比,初始联合甲氨蝶呤并未显著改善阿达木单抗的总体药物生存率。
  • 联合组因不良事件停药常见;为保障医疗可及性,可在个体患者中考虑阿达木单抗联合甲氨蝶呤治疗。

研究设计与样本

  • 荷兰和比利时的多中心随机对照试验,纳入61例未使用过阿达木单抗的中重度斑块状银屑病患者。
  • 通过集中在线随机化服务进行随机分组,每12周随访一次直至第145周,结局评估者设盲。
  • 收集药物生存率、有效性、安全性、药代动力学和免疫原性数据,进行描述性分析,按最初随机分组分析,对生物制剂不依从的患者排除分析。

主要发现

  • 61例患者纳入研究,1年后37例(阿达木单抗组17例,阿达木单抗联合甲氨蝶呤组20例)继续进入随访研究。
  • 第109周药物生存率联合组54.8% vs 单药组41.4%(p=0.326),第145周联合组51.6% vs 单药组41.4%(p=0.464),呈联合组药物生存期更长的趋势但无统计学显著差异。
  • 第145周时,联合组13例中7例仍接受甲氨蝶呤治疗。
  • 单药组完成研究的12例中4例产生抗药抗体,联合组13例中3例产生抗药抗体。

关键数值与推荐

  • 第109周药物生存率:阿达木单抗联合甲氨蝶呤组54.8% vs 阿达木单抗单药组41.4%(p=0.326)。
  • 第145周药物生存率:阿达木单抗联合甲氨蝶呤组51.6% vs 阿达木单抗单药组41.4%(p=0.464)。
  • 第145周时联合组13例中7例仍使用甲氨蝶呤。
  • 单药组完成研究的12例中4例产生抗药抗体,联合组13例中3例产生抗药抗体。

临床怎么用

  • 作者认为,为保障医疗可及性,可在个体患者中考虑阿达木单抗联合甲氨蝶呤治疗。
  • 联合组因不良事件停药常见。

局限性

  • 原文称本研究为小型研究(small study)。
  • 对生物制剂不依从的患者被排除分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-drug antibodies (ADA) are formed in patients treated with adalimumab (ADL). This might increase clearance of ADL, potentially causing a (secondary) non-response. Combination therapy of ADL and methotrexate (MTX) reduces ADA levels and has a clinical benefit in rheumatologic diseases. In psoriasis however, the long-term effectiveness and safety have not been studied. OBJECTIVES: To investigate the three-year follow-up data of ADL combined with MTX compared to ADL monotherapy in ADL-naive patients with moderate to severe plaque type psoriasis. METHODS: We conducted a multicentre RCT in the Netherlands and Belgium. Randomization was performed by a centralized online randomization service. Patients were seen every 12 weeks until week 145. Outcome assessors were blinded. We collected data on drug survival, effectiveness, safety, pharmacokinetics and immunogenicity of patients that started ADL combined with MTX compared to ADL monotherapy. We present descriptive analysis and patients were analysed according to the group initially randomized to. Patients becoming non-adherent to the biologic were excluded from analyses. RESULTS: Sixty-one patients were included and 37 patients (ADL group n = 17, ADL + MTX group n = 20) continued in the follow-up study after 1 year. After 109 weeks and 145 weeks, there was a trend towards longer drug survival in the ADL + MTX group compared to the ADL group (week 109: 54.8% vs. 41.4%; p = 0.326, week 145: 51.6% vs. 41.4%; p = 0.464). At week 145, 7/13 patients were treated with MTX. In the ADL group, 4/12 patients that completed the study developed ADA, and 3/13 in the ADL + MTX group. CONCLUSIONS: In this small study, there was no significant difference in ADL overall drug survival when it was initially combined with MTX, compared to ADL alone. Discontinuation due to adverse events was common in the combination group. To secure accessible healthcare, combination treatment of ADL and MTX can be considered in individual patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. van Huizen AM, van der Kraaij GE, Busard CI, et al. Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial. J Eur Acad Dermatol Venereol. 2023. PMID: 37014287. doi:10.1111/jdv.19089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。